论文部分内容阅读
目的对利奈唑胺在重症监护病房(ICU)脓毒症治疗方面的疗效和安全性进行评价。方法对我院经利奈唑胺治疗脓毒症患者52例的资料进行分析,评价其疗效,同时记录治疗期间的不良反应。结果本组52例患者中总有效率为75.0%。治疗后患者APACHEⅡ评分、血乳酸及炎性因子TNF-a、IL-6均较治疗前明显降低,与治疗前比较差异具有显著性(P<0.05)。6例发生不良反应,不良反应发生率为11.5%,未经特殊处理,停药后恢复。结论利奈唑胺治疗脓毒症效果显著,安全性较高,有指征的应用对提高救治率,挽救患者生命具有积极的作用。
Objective To evaluate the efficacy and safety of linezolid in the treatment of sepsis in intensive care unit (ICU). Methods The data of 52 cases treated with linezolid in patients with sepsis in our hospital were analyzed to evaluate the curative effect and record the adverse reactions during the treatment. Results The total effective rate of 52 patients in this group was 75.0%. After treatment, APACHEⅡscore, blood lactic acid and inflammatory cytokines TNF-a, IL-6 were significantly lower than those before treatment, which were significantly different from those before treatment (P <0.05). 6 cases of adverse reactions, the incidence of adverse reactions was 11.5%, without special treatment, withdrawal after recovery. Conclusion Linezolid treatment of sepsis with significant effect, high safety, indications of the application to improve the treatment rate and save the lives of patients have a positive effect.